Risk factors and outcome of infections with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in kidney transplant recipients

Infection

Volumn 43, Issue 3, 2015, Pages 315-323

  Freire, Maristela P ^a   Abdala, Edson ^b   Moura, Maria L ^a   de Paula, Flávio Jota ^b   Spadão, Fernanda ^a   Caiaffa Filho, Hélio H ^b   David Neto, Elias ^b   Nahas, William C ^b   Pierrotti, Ligia C ^b  

^a Working Committee for Hospital Epidemiology and Infection Control   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Carbapenem resistant; Epidemiology; K. pneumoniae; Kidney transplantation; Mortality; Risk factor

Indexed keywords

AMIKACIN; BASILIXIMAB; CARBAPENEM; COLISTIN; CREATININE; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; POLYMYXIN; THYMOCYTE ANTIBODY; TIGECYCLINE; BACTERIAL DNA; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIUM CULTURE; BLOOD TRANSFUSION; BLOODSTREAM INFECTION; CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE; CLINICAL ARTICLE; COHORT ANALYSIS; CONCURRENT INFECTION; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INVASIVE DEVICE; KIDNEY TRANSPLANTATION; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MALE; MEDICAL DEVICE; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; ORGAN TRANSPLANTATION; OSTEOMYELITIS; PNEUMONIA; POLYMERASE CHAIN REACTION; RECURRENT DISEASE; RISK FACTOR; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURGICAL INFECTION; SURGICAL MORTALITY; SURGICAL WOUND; SURVIVAL; URETER STENT; URINARY TRACT INFECTION; ENZYMOLOGY; GENETICS; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTIONS; MICROBIOLOGY; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SECRETION (PROCESS); SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

AGED; BACTERIAL PROTEINS; BETA-LACTAMASES; DNA, BACTERIAL; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930272437     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-015-0743-4     Document Type: Article

References (41)

1. Jacoby GA, Munoz-Price LS. The new b-lactamases. N Engl J Med. 2005;352:380–91.
2. Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother. 2005;56:128–32.
3. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13:785–96.
4. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228–36.
5. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol. 2009;30:1180–5.
6. Gyung Y, Choi SH, Choo EJ, et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist. 2005;11:165–8.
7. Orsi GB, Bencardino A, Vena A, et al. Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case–control study. Infection. 2013;41:61–7.
8. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099–106.
9. Schwaber MJ, Klarfeld-Lidji S. Navon-Venezia, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008;52:1028–33.
10. Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology and outcome. Antimicrob Agents Chemother. 2008;52:1413–8.
11. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of Combination Therapy. Clin Infect Dis. 2012;55:943–50.
12. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis. 2012;14:198–205.
13. Clancy CJ, Chen L, Shields RK, et al. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant. 2013;13:2619–33.
14. Lübbert C, Becker-Rux D, Rodloff AC, et al. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case—control analysis. Infection. 2014;42:309–16.
15. Taglietti F, Di Bella S, Galati V, Topino S, Iappelli M, Petrosillo N. Carbapenemase-producing Klebsiella pneumoniae-related mortality among solid organ-transplanted patients: do we know enough? Transpl Infect Dis. 2013;15:E164–5.
16. Kalpoe JS, Sonnenberg E, Factor SH, et al. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl. 2012;18:468–74.
17. Cicora F, Mos F, Paz M, Allende NG, Roberti J. Infections with blaKPC-2-producing Klebsiella pneumoniae in renal transplant patients: a retrospective study. Transpl Proc. 2013;45:3389–93.
18. Simkins J, Muggia V, Cohen HW, Minamoto GY. Carbapenem-resistant Klebsiella pneumoniae infections in kidney transplant recipients: a case-control study. Traspl Infect Dis. 2014;16:775–82.
19. Horan CT, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infec Control. 2008;36:309–32.
20. Ljungman P, Griffiths P, Paya C. Definitions of Cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–7.
21. Freire MP, Antonopoulos IM, Piovesan AC et al. Amikacin prophylaxis and risk factors for surgical site infection after kidney transplantation. Transplantation. 2014; (Epub ahead of print).
22. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement; M100-S22. Wayne: CLSI; 2012.
23. ® label information. http://www.accessdata.fda.gov/drugsatfdadocs/label/2010/021821s027lbl.pdf
24. European Committee on Antimicrobial Susceptibility Testing. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.3_pdf. Accessed 6 Jan 2014.
25. Satlin MJ, Jenkins SG, Walsh TJ. The Global challenge of Carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;58:1274–83.
26. Wilson CH, Rix DA, Manas DM. Routine intraoperative ureteric stenting for kidney transplant recipients. Cochrane Database Syst Rev. 2013, 6:CD004925.
27. Lee JR, Bang H, Dadhania D, et al. Independent risk factors for urinary tract infection and for subsequent bacteremia or acute cellular rejection: a single-center report of 1166 kidney allograft recipients. Transplantation. 2013;96:732–8.
28. Hyle EP, Ferraro MJ, Silver M, Lee H, Hoope DC. Ertapenem-resistant Enterobacteriaceae: risk Factors for acquisition and outcomes. Infect Control Hosp Epidemiol. 2010;31:1242–9.
29. Vidal E, Torre-Cisneros J, Blanes M, et al. Bacterial urinary tract infection after solid organ transplantation in the RESITRA cohort. Transpl Infect Dis. 2012;14:595–603.
30. Sorto R, Irizar SS, Delgadillo G, Alberú J, Correa-Rotter R, Morales-Buenrostro LE. Risk factors for urinary tract infections during the first year after kidney transplantation. Transplant Proc. 2010;42:280–1.
31. Bodro M, Sabe N, Tubau F, et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation. 2013;96:843–9.
32. Linares L, Cervera C, Hoyo I, et al. Klebsiella pneumoniae infection in solid organ transplant recipients: epidemiology and antibiotic resistance. Transplant Proc. 2010;42:2941–3.
33. Winters HA, Parbhoo RK, Schafer JJ, Goff DA. Extended-spectrum beta-lactamase-producing bacterial infections in adult solid organ transplant recipients. Ann Pharmacother. 2011;45:309–16.
34. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56:2108–13.
35. Zavascki AP, Bulitta JB, Landersdorfe CB. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther. 2013;11:1333–53.
36. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with Gram-Negative bacteria. Clin Microbiol Rev. 2012;25:450–70.
37. Zavascki AP, Goldani LZ, Cao G, et al. Pharmacokinetics of intravenous polymyxin b in critically ill patients. Clin Infect Dis. 2008;47:1298–304.
38. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284–94.
39. Shields RK, Clancy CJ, Gillis LM, et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One. 2012;7:e52349.
40. Freire MP, Van Der Heijden IM, Prado GV, et al. Polymyxin use as risk factor for colonization or infection with polymyxin-resistant Acinetobacter baumannii after liver transplantation. Transpl Infect Dis. 2014;16:369–78.
41. Freire MP, Pierrotti LC, Filho HH et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients. Eur J Clin Microbiol Infect Dis. 2015;34:277–86.